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Association Between Respiratory Syncytial Virus-
Associated Acute Lower Respiratory Infection in Early Life 
and Recurrent Wheeze and Asthma in Later Childhood
Ting Shi,1,a Yujing Ooi,1,a Ei Mon Zaw,1 Natasa Utjesanovic,1 Harry Campbell,1,  Steve Cunningham,2,3 Louis Bont,4,5 and Harish Nair1,5, ; for the RESCEU 
Investigators
1Centre for Global Health Research, Usher Institute of Population Health Sciences and Informatics, and 2Centre for Inflammation Research, University of Edinburgh, and 3Royal Hospital for Sick 
Children, Edinburgh, United Kingdom; 4Department of Pediatric Infectious Diseases and Immunology, University Medical Center Utrecht and 5Respiratory Syncytial Virus Network Foundation, Zeist, 
The Netherlands
Background. Recurrent wheeze and asthma in childhood are commons causes of chronic respiratory morbidity globally. We 
aimed to explore the association between respiratory syncytial virus (RSV) infection in early life and subsequent respiratory sequelae 
up to age 12 years.
Methods. We estimated the strength of association by 3 control groups and 3 follow-up age groups, with data from studies pub-
lished between January 1995 and May 2018. We also estimated associations by diagnostic criteria, age at infection, and high-risk 
population.
Results. Overall, we included 41 studies. A statistically significant association was observed between early life RSV infection and 
subsequent childhood recurrent wheeze, in comparison to those who were healthy or those without respiratory symptoms: OR 3.05 
(95% confidence interval [CI], 2.50–3.71) for 0 to <36 months follow-up age; OR 2.60 (95% CI, 1.67–4.04) for 36–72 months; and 
OR 2.14 (95% CI, 1.33–3.45) for 73–144 months. For the subsequent development of asthma, a statistically significant association 
was observed only in relation to those aged 73–144 months at follow-up: OR 2.95 (95% CI, 1.96–4.46).
Conclusions. Further studies using standardized definitions and from diverse settings are needed to elucidate the role of 
confounders and provide more robust estimates.
Keywords. respiratory syncytial virus; recurrent wheeze; asthma; children.
Respiratory syncytial virus (RSV)-associated acute lower respi-
ratory infection (ALRI) is a major cause of hospital admissions 
in young children, resulting in a substantial burden on health 
care services. About 45% of hospitalization and in-hospital 
deaths due to RSV-ALRI occur in children during the first 
6  months of life [1]. The development of a safe and effective 
vaccine to protect young children against RSV infection could 
have a substantial effect on disease burden in this age group. 
A  monoclonal antibody is available for RSV prophylaxis for 
at-risk infants; a novel monoclonal antibody and pediatric and 
maternal candidate vaccines are in the late stages of develop-
ment [2]. These prophylaxis or vaccination strategies may 
protect the infants against acute RSV illness during their first 
months of life. Meanwhile, early childhood RSV-ALRI has been 
reported to have an association with subsequent development 
of wheeze-associated disorders in childhood [3, 4]. Recurrent 
wheeze and asthma in childhood are a common cause of mor-
bidity globally, that lead to decreased quality of life, frequent 
health care utilization with high health economic costs, and 
financial burden to families [5, 6]. Whilst some recurrent 
wheezing may resolve spontaneously, others persist into adult-
hood. The public health and economic value of RSV prophy-
laxis and vaccines would be greater if they also decreased the 
prevalence and severity of wheeze-associated disorders.
The aim of this review is to explore whether there is an as-
sociation between RSV infection in early life and subsequent 
respiratory sequelae (recurrent wheeze or asthma) up to age 
12 years.
METHODS
Search Strategy and Selection Criteria
We conducted a systematic review across 9 databases (including 
3 Chinese databases) following the approach detailed in the 
PRISMA guidelines [7]. Tailored search strategies were devel-
oped and applied to search Medline, Embase, Global Health, 
Web of Science, Cumulative Index to Nursing and Allied Health 
Literature, Global Index Medicus, China National Knowledge 
Infrastructure (CNKI), Wanfang Data, and Chongqing VIP 
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databases (Supplementary Material Strategy). All searches were 
limited to between January 1995 and May 2018. No publica-
tion status criteria or language restrictions were applied. We in-
cluded studies that fulfilled the selection criteria described in 
Supplementary Panel 1.
Three investigators (T. S., Y. O., and E. M. Z.) conducted in-
dependent literature searches and extracted data using stand-
ardized data extraction templates. One investigator (T. S.) 
whose first language is Chinese performed the search and data 
extraction from Chinese language databases (CNKI, Wanfang, 
and Chongqing VIP). Any uncertainties regarding relevance or 
inclusion were discussed with and adjudicated by T. S.
The protocol of this review was published in the PROSPERO 
database (No. CRD42018095112).
Definitions
The population under investigation consists of children up to 
12 years old because the literature suggests that lung function 
is lost early in life and this age cutoff should allow explora-
tion of the association with early life respiratory virus infec-
tion [8]. This statement assumes that respiratory morbidity 
varies by age from infancy to adolescence and the impact of 
early life RSV infection appears to diminish in later child-
hood. The exposure group was defined as RSV infection with 
laboratory confirmation in the first year of life (including 
those younger than 2/3  years). The control group was de-
fined as infants without respiratory symptoms (RSV/noRS); 
or respiratory infection associated with other pathogens in-
cluding rhinovirus (RSV/other); or only rhinovirus infection 
(RSV/RV) (Supplementary Panel 2). Outcomes were recurrent 
wheeze and asthma. The follow-up age group (up to 12 years 
old) were categorized into 3 subgroups (0 to <36  months, 
36–72 months, and 73–144 months) in order to evaluate the 
association by age.
Statistical Analysis
We standardized the results of all the included studies as odds 
ratios (ORs) of detecting the occurrence of the outcome in in-
fants with RSV infection compared to the control group with 
accompanying 95% confidence intervals (95% CIs) to facilitate 
interpretation and comparison. We applied a continuity cor-
rection of 0.0005 if the outcome was detected in 1 group but 
not the other [9]. This allowed calculation of an OR for these 
instances and enabled inclusion in subsequent metaanalyses. 
Furthermore, adjusted odds ratios (aORs) were also extracted, 
where possible. These were used preferentially in subsequent 
calculations and analyses.
Using STATA (version 13.0), we performed a metaanalysis 
of outcome-specific ORs and reported pooled estimates with 
corresponding 95% CIs using the random effects model 
(DerSimonian-Laird method) because the included studies 
are heterogeneous in various aspects and thus are assumed 
to have different effect sizes [10]. Each outcome was assessed 
separately in comparison to 3 control groups. This led to 6 
groups of results in total. Within each group, the result was 
reported as per the above predefined age subgroups. Subgroup 
analysis stratified by outcome diagnosis (physician diagnosed 
or parent reported) and age at RSV infection (0–11  months 
and 0–23  months) were carried out to explore the effect of 
possible confounders. Similarly, sensitivity analyses in high-
risk populations (those with prematurity or atopy) were also 
conducted.
Quality Assessment
Quality assessment at the individual study level was car-
ried out using the adapted Downs and Black checklist [11]. 
Items that were not applicable (adverse effects, blinding of 
subjects, compliance, randomization, concealment) were re-
moved. The power criteria have been defined as having score 
1 for providing power calculation and 0 if not. This resulted 
in evaluation of 22 variables with a maximum score of 22. 
A score of less than 12 (out of 22) was defined as a low-quality 
study.
RESULTS
We identified 4520 records and only 41 studies, including about 
234 000 children, fulfilled our inclusion criteria (Supplementary 
Figure 1). Although the search was carried out for articles pub-
lished from 1995, most (37/41) included studies published since 
2000. Four studies were conducted within developing countries 
while 37 were from industrialized countries. One study was 
from a rural setting, 37 from urban areas, and 3 from a mix 
of urban and rural areas. There was considerable variation 
in the design of included studies. Ten studies were from ret-
rospective cohorts while 31 were prospective cohort studies. 
The majority of RSV cases were identified from inpatients (31 
studies) while the remaining recruited cases from outpatients, 
emergency departments, clinic visits, or community. Twenty-
eight studies reported the outcome of recurrent wheeze. Among 
them, 17 studies used infants without respiratory symptoms or 
healthy infants as controls, 14 studies reported outcome data 
for infants with other pathogen-associated respiratory in-
fection, and 3 studies had data on infants with rhinovirus as 
the control group. Twenty-six studies reported the outcome 
of asthma. Among them, 12, 16, and 3 studies were available, 
respectively, reporting data for the 3 control groups. A  table 
describing features of the studies is available in Supplementary 
Table 1. Supplementary Tables 2–7 summarize the key charac-
teristics and result of each included study under each category 
(6 categories under the combination of 2 outcomes and 3 con-
trol groups). The metaanalyses results for both outcomes are 
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RSV Infection and Recurrent Childhood Wheeze
In the RSV/noRS group there were 10, 7, and 6 studies, re-
spectively, for the 3 follow-up age groups, 0 to <36  months, 
36–72 months, and 73–144 months. The pooled metaanalysis 
ORs were 3.05 (CI, 2.50–3.71), 2.60 (95% CI, 1.67–4.04), and 
2.14 (95% CI, 1.33–3.45), respectively. In the RSV/other group 
there were 7, 7, and 2 studies for the 3 follow-up age groups. 
The OR metaestimates were 0.79 (95% CI, 0.32–1.95) for 0 to 
<36 months and 0.81 (95% CI, 0.39–1.71) for 36–72 months, 
respectively. For the RSV/RV group there were only 3 studies, 
all of which had follow-up of 36–72 months, which resulted in 
the OR metaestimate of 0.41 (95% CI, 0.20–0.83).
We observed that the OR metaestimates for physician-
diagnosed recurrent wheeze and parent-reported recurrent 
wheeze in the RSV/noRS group for children aged 0 to <36 months 
were 3.40 (95% CI, 2.60–4.46) and 2.48 (95% CI, 1.60–3.85), 
respectively. We also estimated that the OR metaestimates for 
recurrent wheeze in the RSV/other group stratified by age at 
RSV infection (0–11  months and 0–23  months) were 2.11 
(95% CI, 1.42–3.12) and 0.30 (95% CI, 0.10–0.97), respectively 
(Supplementary Table 8 reports results for 0–11 months). In the 
RSV/noRS group (age 0 to <36 months), sensitivity analysis in 
premature infants indicated an OR metaestimate of 3.20 (95% 
CI, 1.82–5.61) compared to 3.06 (95% CI, 2.63–3.55) in the full-
term infants.
RSV Infection and Asthma
In the RSV/noRS group, there were 2, 2, and 9 studies, re-
spectively, for the 3 follow-up age groups, 0 to <36  months, 
36–72  months, and 73–144  months. The OR metaestimate 
for the follow-up age group of 73–144 months was 2.95 (95% 
CI, 1.96–4.46). In the RSV/other group there were 2, 7, and 7 
studies for the 3 follow-up age groups. The OR metaestimates 
for the 36–72 months and 73–144 months follow-up age groups 
were 1.28 (95% CI, 0.84–1.95) and 0.54 (95% CI, 0.28–1.06), 
respectively. For the RSV/RV group, there were only 3 studies 
and each study had a different follow-up age group, which pre-
cluded any metaanalyses.
Our subgroup analysis stratified by age at RSV infection 
(0–11  months and 0–23  months) for the follow-up age of 
73–144 months demonstrated OR metaestimates of 3.68 (95% 
CI, 1.92–7.04) and 2.28 (95% CI, 1.44–3.60), respectively, for 
the RSV/noRS group (Supplementary Table 8). Similarly, the 
OR metaestimates were 0.52 (95% CI, 0.17–1.63) for age at 
RSV infection 0–11 months and 0.41 (95% CI, 0.17–1.01) for 
age 0–23 months, for the RSV/other group. Sensitivity analysis 
focusing on atopic infants indicated that the OR metaestimate 
was 1.73 (95% CI, 1.13–2.64) in the RSV/other group for the 
36–72 months follow-up age group.
The score from the quality assessment varied from 11 to 19 
after taking into consideration 22 items. There were 4 studies 
with low quality (score <12 out of a maximum score of 22). 
Excluding these studies did not change the results substantially, 
perhaps due to the limited number of studies deemed to be of 
low quality.
DISCUSSION
This is the first systematic review to evaluate and summarize 
the literature on the association between RSV infection in early 
life and childhood recurrent wheeze and asthma, stratified by 
3 control groups and 3 follow-up age groups. Our aim was to 
best synthesize evidence on this association taking into consid-
eration a list of confounders as completely as possible. A pre-
vious publication combined all studies and outcome measures, 
making it difficult to translate findings into public health 
policy making [12]. This review also identified a number of 
new studies. Our review summarized data from 41 studies. We 
demonstrated consistent evidence in support of an association 




No. of Studies OR (95% CI) No. of Studies OR (95% CI)
RSV vs no respiratory symptoms   
 <36 10 3.05 (2.50–3.71) 2 …
 36–72 7 2.60 (1.67–4.04) 2 …
 >72 6 2.14 (1.33–3.45) 9 2.95 (1.96–4.46)
RSV vs other pathogens   
 <36 7 0.79 (0.32–1.95) 2 …
 36–72 7 0.81 (0.39–1.71) 7 1.28 (0.84–1.95)
 >72 2 … 7 0.54 (0.28–1.06)
RSV vs rhinovirus   
 <36 0 … 1 …
 36–72 3 0.41 (0.20–0.83) 1 …
 >72 0 … 1 …
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between early life RSV infection and subsequent childhood 
recurrent wheeze in the RSV/noRS group: OR 3.05 (95% CI, 
2.50–3.71) for 0 to <36 months follow-up age, OR 2.60 (95% CI, 
1.67–4.04) for 36–72 months, and OR 2.14 (95% CI, 1.33–3.45) 
for 73–144  months. Although the strength of the association 
decreased with age, it remained statistically significant. A sim-
ilar statistically significant association was observed for subse-
quent asthma episodes in the RSV/noRS group: OR 2.95 (95% 
CI, 1.96–4.46) for 73–144 months follow-up age (data not avail-
able in other follow-up age groups). However, the association 
was not significant for either outcome in the RSV/other group. 
In the RSV/RV group, the association was negatively significant 
for recurrent wheeze (OR, 0.41 [95% CI, 0.20–0.83]) and uncer-
tain for asthma due to a limited number of studies, which might 
indicate that rhinovirus could play a comparable or even more 
important role in childhood recurrent wheeze.
Several subgroup analyses and sensitivity analyses were avail-
able from this study. The association between RSV infection 
during infancy and childhood recurrent wheeze was slightly 
higher in the physician-diagnosed strata (OR, 3.40 [95% CI, 
2.60–4.46]) compared to parent reported (OR, 2.48 [95% CI, 
1.60–3.85]) with overlapping 95% CIs (only data in the RSV/
noRS group with 0 to <36 months follow-up age). This might 
demonstrate the difference in the ability of physicians and 
parents to accurately diagnose recurrent wheeze. In the high-
risk premature cohort population, a slightly stronger associa-
tion (with overlapping CIs) was observed with recurrent wheeze 
(RSV/noRS group with 0 to <36  months follow-up age). The 
definition of prematurity varied across studies from <37 weeks 
to 32–35 weeks of gestational age. In another high-risk cohort 
population (atopy), a stronger association was observed with 
asthma (RSV/other group with 36–72 months follow-up age). 
Children at high risk of atopy were defined as having at least 1 
parent with respiratory allergies and/or a history of physician-
diagnosed asthma. All these subgroup analyses and sensitivity 
analyses were based on a limited number of studies and the 
results were usually only available under specific subgroups. 
Consistent and more robust results would require more studies.
Although a thorough search was carried out across 9 data-
bases, including 3 Chinese language databases, only 41 studies 
from the published literature were identified meeting our eli-
gibility criteria. The number of studies was even smaller when 
metaanalyses were carried out stratified by outcome, control 
group, and follow-up age group. Limited studies were available 
for subgroup or sensitivity analyses to explore the heteroge-
neity by diagnostic criteria (physician diagnosed or parents re-
ported), age at RSV infection, and high-risk cohort population 
(prematurity, atopy). Most studies (37/41) were from industrial-
ized countries and from urban areas, thus evaluating the influ-
ence of region or setting on the association of interest was not 
possible. Also, there were insufficient studies to evaluate the im-
pact of severity of RSV infection in early life on the association 
because RSV cases in most studies (31/41) were identified from 
inpatients. Similarly, 31 of the 41 studies were prospective co-
hort studies. Moreover, the sample size in the RSV exposure 
group varied from 20 to 1266 and from 9 to 138  326 in the 
control group. The small sample size undoubtedly contributed 
to the imprecise 95% CIs calculation of some ORs. Therefore, 
more studies with larger sample sizes are required to produce 
more robust estimates for the above variables.
Apart from the variables discussed above, there were many 
other confounders that should be considered in order to eval-
uate the true association. Only 9 studies recruited a control 
group matched on date of birth, gender, residence, or eth-
nicity. Most studies (30/41) reported crude OR without taking 
into consideration other confounders. The remaining studies 
(11/41) reported adjusted OR, adjusting for 1 or several of 
the following: age, gender, prematurity, birth weight, season-
ality, duration of breastfeeding, maternal age, maternal educa-
tion, maternal smoking during pregnancy, maternal history of 
asthma, ethnicity, care-seeking behavior, day care attendance, 
or siblings. Coinfection detection was not considered in most 
studies. For those studies that did consider this, 1 study ex-
cluded coinfection while 8 included coinfection. Some studies 
(24/41) compared the characteristics between exposure group 
and the control group and others did not. Due to the nature of 
the study design (retrospective or prospective cohort studies), 
some participants were lost to follow-up during the study 
period. Only a few studies (8/41) discussed the characteristics 
of participants who were lost to follow-up and their possible 
impact on the result.
The definitions for recurrent wheeze and asthma varied sub-
stantially. For recurrent wheeze, ≥3 episodes of wheezing in the 
last 12 months was a commonly used definition in the majority 
of studies (13/28). However, ≥1 episode per year (11/28) and any 
wheeze during the follow-up (4/28) were also used. For asthma, 
some studies used current medication for asthma, or physician 
diagnosed asthma, or required symptoms of asthma within last 
12 months, while others also accepted asthma diagnosis at any 
point during follow-up. There was no standardized asthma def-
inition. Only 4 studies utilized the validated International Study 
of Asthma and Allergies in Childhood questionnaire. Research 
on respiratory morbidity suffers from a lack of adherence to in-
ternational definitions. Four studies with a follow-up age group 
<5 years old also reported asthma outcome; however, this may 
pose diagnostic difficulty as objective testing such as spirometry 
is more challenging in young children [13].
Six studies evaluated the association between RSV prophy-
laxis (palivizumab or motavizumab) in infancy and childhood 
recurrent wheeze or asthma [14–19]. These were excluded from 
the analysis as they were designed (usually randomized con-
trolled trials) to answer a slightly different research question 
that would be more appropriate to assess in a future analysis, 
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between RSV prophylaxis (or vaccine) strategy in early life and 
childhood respiratory sequelae. Similarly, among these studies, 
many variations existed: they recruited cases (receiving RSV 
prophylaxis) and controls (not receiving RSV prophylaxis) from 
different settings, used different case/control ascertainment, ap-
plied different definitions for the controls, investigated different 
outcomes, used different definitions and diagnosis methods for 
outcome, and reported varied follow-up age groups. In these 
studies, the association between RSV prophylaxis during in-
fancy and childhood recurrent wheeze varied from OR 0.25 
(95% CI, 0.09–0.72) to 1.10 (95% CI, 0.60–2.00). For asthma, 
there was only 1 study reporting the association (OR, 0.52 
[95% CI, 0.31–0.87]) [19]. More studies to assess the effects of 
RSV prevention on these childhood respiratory outcomes are 
required.
The association between RSV infection during infancy and 
subsequent childhood recurrent wheeze and asthma may not 
necessarily indicate causation. Other criteria should be taken 
into consideration first before causality can be concluded. 
On applying Bradford Hill criteria [20], we observed that the 
strength of association varied across the control groups and 
follow-up age groups. The association was not specific but did 
have a temporal sequence between exposure and outcome. The 
remaining criteria were uncertain due to either a lack of evi-
dence or there being inconsistent evidence available. However, 
the absence of these Bradford Hill criteria does not rule out a 
possible causal relationship. There are many methodological is-
sues that should be taken into consideration to define causality 
[21]. Therefore, the association between RSV infection during 
infancy and childhood respiratory sequelae should be inter-
preted carefully.
There is considerable international attention on RSV infec-
tion in young children at this time when novel vaccine and 
antiviral strategies are being evaluated and prioritized [2, 22] 
and more accurate estimate on the long-term effect of RSV 
on childhood recurrent wheeze and asthma would help to 
plan for maternal RSV vaccines as well as future policies and 
interventions.
In conclusion, this review provides some evidence sup-
porting an association between RSV infection in early life 
and childhood recurrent wheeze and asthma. However, this 
is only when comparing to infants without respiratory symp-
toms. Further studies using standard definitions are needed 
to elucidate the surrounding confounders and provide more 
robust estimates regarding the association between viral 
respiratory disease in early life and childhood respiratory 
sequelae.
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